Moderna’s Coronavirus Vaccine


Hannah Stai, News Editor

Ranking as the second vaccine in the U.S. with a high success rate, Moderna introduces a new coronavirus vaccine with a 94.5% effectiveness rate.

Dr. Anthony Fauci, the top infectious disease doctor in the U.S., has congratulated the company; “These are obviously very exciting results. It’s just as good as it gets — 94.5% is truly outstanding.”

“It is absolutely amazing to be able to develop this vaccine and see the ability to prevent symptomatic disease with such high efficacy.” Dr. Tal Zachs, Moderna’s chief medical officer, was ecstatic to share the results.

Dr. Facui has predicted that vaccinations against COVID-19 should begin in the second half of December. At first, the vaccinations will be given to the high risk groups such as health care workers, the elderly, and people with underlying medical conditions. Fauci hopes the vaccine will be given out to the public masses by next spring. 

Moderna’s vaccine trial included 15,000 study participants who were given a placebo. 90 of the participants developed COVID-19, and only 11 of which developed severe forms of the virus. The trial also included another 15,000 participants who were actually given the vaccine. Only five were reported with developing COVID-19 and none of the participants became severely ill. 

Moderna also claims there are no serious side effects with the vaccine, and that only a small percentage of participants experienced mild symptoms like body aches or headaches throughout the days after receiving the vaccine. 

With effective rates like Moderna’s, an end to this global pandemic is in sight.